NCT00502086

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Catalysis SL · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, gastrointestinal bleeding, sepsis and hepatocellular carcinoma) of patients with cirrhosis of the liver secondary to HCV infection in comparison with placebo, during 96 weeks of treatment.

Conditions

• Cirrhosis
• Chronic Hepatitis C

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Viusid (nutritional supplement)	Viusid three sachets daily during 96 weeks
OTHER	Placebo	Placebo three sachets daily during 96 weeks

Timeline

• Start date: 2005-05-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2007-07-17
• Last updated: 2011-02-11

Locations

1 site across 1 country: Cuba